Articles By Cyndi Root

51. UCSF, CDRD Partner To Address 'Valley of Death' In Drug Development 10/23/2014

    The University of California San Francisco (UCSF) and The Center for Drug Research and Development (CDRD) have partnered to address the ‘Valley of Death’, the phase between therapy discovery and commercialization. UCSF announced the partnership in a press release, stating that the collaboration seeks to take the University’s laboratory inventions into the marketing stage.

52. Batu Biologics Licenses Novel Oncology Peptide Drugs From UC San Diego 10/21/2014

    Batu Biologics has acquired exclusive licensing rights to novel peptide drugs for oncology targets from the University of California San Diego (UCSD).

53. Rich Pharmaceuticals Acquires Phorbol Esters For Hodgkin's Lymphoma 10/17/2014

    Rich Pharmaceuticals has acquired the patents, intellectual property, and commercialization rights for phorbol esters in the treatment of Hodgkin's lymphoma.

54. GeoVax To Develop Ebola Vaccines With CDC 10/8/2014

    As many drug companies are in a race to the first FDA-approved treatment for Ebola, GeoVax Labs has announced its own plans to throw its hat into the ring.

55. WuXi PharmaTech Acquires XenoBiotic Laboratories, Expands U.S. Presence 10/3/2014

    Earlier this week, R&D outsourcing company WuXi PharmaTech announced its acquisition of XenoBiotic Laboratories (XBL), a CRO based in Plainsboro, NJ. The acquisition, announced in a press release, allows WuXi to provide expanded service and support to U.S. customers.

56. Novo Nordisk To Focus On Obesity With New Seattle Research Unit 9/30/2014

    Novo Nordisk is focusing efforts on obesity treatments and is building a new obesity research unit in Seattle, WA. The company announced the initiative in a press release. The Novo Nordisk Obesity Research Unit will initially employ 10 people, reaching 60 by the end of 2016. The new center will concentrate on basic research and treatments for obesity. Mads Krogsgaard Thomsen, EVP and CSO at Novo Nordisk, said, “Our ambition is to drive scientific progress in the obesity disease area and through this, identify and develop new treatment options for people with obesity.”

57. Gilead's HIV Regimen Pulls Weight In Phase 3 Studies 9/25/2014

    Gilead Sciences plans U.S. and EU regulatory filings in Q4 2014 for HIV drug tenofovir alafenamide (TAF) following good news from two Phase 3 studies. The announcement in a press release revealed that TAF showed non-inferiority to the company’s other treatment for HIV, Stribild, and demonstrated more favorable renal and bone safety.

58. Genocea Receives Funding For Malaria Vaccine R&D 9/24/2014

    Genocea Biosciences has received a $1.2 million grant from the Bill & Melinda Gates Foundation to identify malaria vaccine candidates.

59. Boehringer Ingelheim, CureVac Partner On Lung Cancer Immunotherapy 9/23/2014

    Boehringer Ingelheim has obtained exclusive rights to develop and market CureVac’s investigational lung cancer immunotherapy. Announced in a press release, the new partnership will focus on the CV9202 vaccine based on CureVac’s mRNA technology (RNActive).

60. Novo Nordisk's Tresiba Shows Efficacy In Children With T1 Diabetes 9/19/2014

    Novo Nordisk’s Tresiba (insulin degludec) demonstrated its effective in children aged 1 to 18 with Type 1 diabetes. The company announced results from the BEGIN YOUNG 1 trial in a press release and at a meeting of the European Association for the Study of Diabetes (EASD). The once-daily basal insulin is approved in over 30 countries but not in the U.S., as the Food and Drug Administration (FDA) has thus far declined to approve it, citing concerns regarding cardiovascular outcomes.